57 related articles for article (PubMed ID: 10211088)
1. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
Van Cutsem E; Cunningham D; Ten Bokkel Huinink WW; Punt CJ; Alexopoulos CG; Dirix L; Symann M; Blijham GH; Cholet P; Fillet G; Van Groeningen C; Vannetzel JM; Levi F; Panagos G; Unger C; Wils J; Cote C; Blanc C; Hérait P; Bleiberg H
Eur J Cancer; 1999 Jan; 35(1):54-9. PubMed ID: 10211088
[TBL] [Abstract][Full Text] [Related]
2. Incorporation of pazopanib in maintenance therapy of ovarian cancer.
du Bois A; Floquet A; Kim JW; Rau J; del Campo JM; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Kimmig R; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Mouret-Reynier MA; Kim JH; Kurzeder C; Lesoin A; Vasey P; Marth C; Canzler U; Scambia G; Shimada M; Calvert P; Pujade-Lauraine E; Kim BG; Herzog TJ; Mitrica I; Schade-Brittinger C; Wang Q; Crescenzo R; Harter P
J Clin Oncol; 2014 Oct; 32(30):3374-82. PubMed ID: 25225436
[TBL] [Abstract][Full Text] [Related]
3. [Discussion about Biomilar development: Filgrastim BS injection and its applications in clinical practice].
Saeki T; Tokuda Y; Takigawa N; Tsurutani J
Gan To Kagaku Ryoho; 2013 Oct; 40(10):1365-76. PubMed ID: 24312985
[No Abstract] [Full Text] [Related]
4. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.
Crown JP; Diéras V; Staroslawska E; Yardley DA; Bachelot T; Davidson N; Wildiers H; Fasching PA; Capitain O; Ramos M; Greil R; Cognetti F; Fountzilas G; Blasinska-Morawiec M; Liedtke C; Kreienberg R; Miller WH; Tassell V; Huang X; Paolini J; Kern KA; Romieu G
J Clin Oncol; 2013 Aug; 31(23):2870-8. PubMed ID: 23857972
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Saltz LB; Cox JV; Blanke C; Rosen LS; Fehrenbacher L; Moore MJ; Maroun JA; Ackland SP; Locker PK; Pirotta N; Elfring GL; Miller LL
N Engl J Med; 2000 Sep; 343(13):905-14. PubMed ID: 11006366
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Douillard JY; Cunningham D; Roth AD; Navarro M; James RD; Karasek P; Jandik P; Iveson T; Carmichael J; Alakl M; Gruia G; Awad L; Rougier P
Lancet; 2000 Mar; 355(9209):1041-7. PubMed ID: 10744089
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis.
Dai J; Chen Y; Gong Y; Wei J; Cui X; Yu H; Zhao W; Gu D; Chen J
Medicine (Baltimore); 2019 Sep; 98(39):e17384. PubMed ID: 31574891
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of irinotecan, 5-fluorouracil, and leucovorin in relapsed or metastatic colorectal cancer as first-line therapy.
Won YW; Lim YH; Park HY; Oh HS; Choi JH; Lee YY; Kim IS; Choi IY; Ahn MJ
Cancer Res Treat; 2004 Aug; 36(4):235-9. PubMed ID: 20368840
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.
Dugan E; Truax R; Meadows KL; Blobe GC; Morse MA; Fernando NH; Gockerman JP; Petros WP; Hurwitz HI
Anticancer Res; 2009 Dec; 29(12):5149-53. PubMed ID: 20044630
[TBL] [Abstract][Full Text] [Related]
10. Modeling biological rhythms in failure time data.
Elkum NB; Myles JD
J Circadian Rhythms; 2006 Nov; 4():14. PubMed ID: 17090302
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.
Mabro M; Artru P; André T; Flesch M; Maindrault-Goebel F; Landi B; Lledo G; Plantade A; Louvet C; de Gramont A
Br J Cancer; 2006 May; 94(9):1287-92. PubMed ID: 16622455
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy.
García-Girón C; García Palomo A; Alonso López C; León Carbonero A; Méndez Ureña M; Adróver Cebrián E; Barceló Galíndez R; Arroyo Yustos M; Alvarez Gallego J
Clin Transl Oncol; 2005 Jul; 7(6):244-9. PubMed ID: 16131447
[TBL] [Abstract][Full Text] [Related]
13. Benefit-risk assessment of irinotecan in advanced colorectal cancer.
Glimelius B
Drug Saf; 2005; 28(5):417-33. PubMed ID: 15853443
[TBL] [Abstract][Full Text] [Related]
14. Second-line therapy for advanced colorectal carcinoma.
Starling N; Cunningham D
Curr Oncol Rep; 2005 May; 7(3):173-80. PubMed ID: 15847707
[TBL] [Abstract][Full Text] [Related]
15. Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study.
Van Cutsem E; Dirix L; Van Laethem JL; Van Belle S; Borner M; Gonzalez Baron M; Roth A; Morant R; Joosens E; Gruia G; Sibaud D; Bleiberg H
Br J Cancer; 2005 Mar; 92(6):1055-62. PubMed ID: 15756271
[TBL] [Abstract][Full Text] [Related]
16. A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.
Delord JP; Pierga JY; Dieras V; Bertheault-Cvitkovic F; Turpin FL; Lokiec F; Lochon I; Chatelut E; Canal P; Guimbaud R; Mery-Mignard D; Cornen X; Mouri Z; Bugat R
Br J Cancer; 2005 Mar; 92(5):820-6. PubMed ID: 15756252
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer.
Saunders MP; Hogg M; Carrington B; Sjursen AM; Allen J; Beech J; Swindell R; Valle JW
Br J Cancer; 2004 Oct; 91(8):1447-52. PubMed ID: 15452550
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
Kuehr T; Ruff P; Rapoport BL; Falk S; Daniel F; Jacobs C; Davidson N; Thaler J; Boussard B; Carmichael J
BMC Cancer; 2004 Jul; 4():36. PubMed ID: 15257756
[TBL] [Abstract][Full Text] [Related]
19. Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study.
Hartmann JT; Oechsle K; Quietzsch D; Wein A; Hofheinz RD; Honecker F; Nehls O; Köhne CH; Käfer G; Kanz L; Bokemeyer C
Br J Cancer; 2003 Dec; 89(11):2051-6. PubMed ID: 14647137
[TBL] [Abstract][Full Text] [Related]
20. Less cytotoxicity to combination therapy of 5-fluorouracil and cisplatin than 5-fluorouracil alone in human colon cancer cell lines.
Chen XX; Lai MD; Zhang YL; Huang Q
World J Gastroenterol; 2002 Oct; 8(5):841-6. PubMed ID: 12378627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
